Igru 25mg Tablet contains Iguratimod 25mg, a disease-modifying antirheumatic drug (DMARD) primarily indicated for the treatment of rheumatoid arthritis and other autoimmune inflammatory conditions. Iguratimod exerts its therapeutic effects by inhibiting the production of pro-inflammatory cytokines and modulating immune responses, thereby reducing joint inflammation, pain, and swelling. It also suppresses the activation of nuclear factor-kappa B (NF-κB), leading to decreased expression of inflammatory mediators. Igru 25mg is administered orally, typically once or twice daily, with dosage adjustments based on clinical response and tolerability. It is recommended for use in patients who have shown inadequate response to conventional therapies such as methotrexate. Common adverse effects include gastrointestinal disturbances, elevated liver enzymes, and mild hematological abnormalities; therefore, regular monitoring of liver function tests and blood counts is advised during treatment. Igru 25mg should be used cautiously in patients with pre-existing liver or kidney impairment. Concomitant use with other immunosuppressants requires careful assessment to avoid additive immunosuppression. This medication is contraindicated in pregnancy and lactation due to potential risks to the fetus and infant. Patients should be advised to report any signs of infection or unusual bleeding promptly.